William Blair downgraded Merus (MRUS) to Market Perform from Outperform after the company agreed to be acquired by Genmab (GMAB) for $97 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS: